State of the Science: Why Funding Pediatric Brain Tumor Research Matters — Insights from Dr. Keren Sturtz of Pfizer

In this short State of the Science spotlight, Dr. Keren Sturtz, Executive Senior Director at Pfizer Oncology Early Clinical Development, shares why breakthroughs in pediatric brain cancer depend on one thing above all: everyone working together.

Dr. Sturtz explains why rare pediatric brain tumors require creative thinkers, strong research infrastructure, and the combined efforts of academic centers, biotech innovators, big pharma, government funding—and philanthropy. She highlights how each part of the ecosystem plays a critical role in getting new treatments across the finish line and into the hands of children who urgently need them.

🎥 Watch the video to hear Dr. Sturtz’s full insights and why Imagine An Answer’s support is so vital to moving the science forward.

💛 Want to help accelerate research?

Donate Now to Imagine An Answer and support life-changing breakthroughs for kids.